Get the Stockscreener App
14.93
0.27%
-0.04
After Hours:
14.85
-0.08
-0.54%
Adlai Nortye Ltd Adr stock is traded at $14.93, with a volume of 223.43K.
It is down -0.27% in the last 24 hours and up +82.52% over the past month.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
See More
Previous Close:
$14.97
Open:
$14.91
24h Volume:
223.43K
Relative Volume:
0.38
Market Cap:
$961.46M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-14.84
EPS:
-1.0062
Net Cash Flow:
-
1W Performance:
+22.68%
1M Performance:
+82.52%
6M Performance:
+929.66%
1Y Performance:
+637.28%
1-Day Range:
$14.68
$15.33
1-Week Range:
$12.07
$15.93
52-Week Range:
$0.8786
$17.25
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Compare ANL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
14.93 | 964.04M | 0 | 0 | 0 | -1.0062 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Leerink Partners | Outperform |
| Feb-13-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-04-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Stock (ANL) Latest News
Adlai Nortye (NASDAQ:ANL) Trading 12.3% HigherHere's Why - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update - MarketBeat
Is Adlai (ANL) stock a strong investment pick (Volatility Increases) 2026-04-27Earnings Miss Stocks - Newser
Adlai Nortye (NASDAQ: ANL) registers $600M shelf; 32.9M ADS resale - Stock Titan
Adlai Nortye (NASDAQ:ANL) Shares Gap DownTime to Sell? - MarketBeat
Adlai Nortye FY2026 EPS Forecast Raised by HC Wainwright - MarketBeat
Adlai Nortye (NASDAQ:ANL) Sets New 1-Year HighStill a Buy? - MarketBeat
Adlai Nortye price target raised to $20 from $16 at H.C. Wainwright - TipRanks
Adlai (ANL) Stock Rallies on Launch (Smart Money Exits) 2026-04-20Fast Rising Stocks - Newser
Adlai Nortye (NASDAQ:ANL) Stock Price Up 18.1%What's Next? - MarketBeat
Adlai Nortye raises $150M in oversubscribed private placement By Investing.com - Investing.com India
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing - Sahm
Adlai Nortye Raises $150 Million in Oversubscribed Private Placement to Advance Cancer Pipeline - TipRanks
Adlai Nortye (NASDAQ:ANL) Shares Gap UpShould You Buy? - MarketBeat
Adlai Nortye raises $150M in oversubscribed private placement - Investing.com
TeraWulf, BRP And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
Adlai Nortye (NASDAQ:ANL) Trading Down 11.7%Here's What Happened - MarketBeat
Adlai Nortye (NASDAQ:ANL) Reaches New 52-Week HighShould You Buy? - MarketBeat
Day's Trending USA Stocks | AVNS: Overnight gain 69.5%, Surges on All-Cash Acquisition Deal by American Industrial Partners - Sahm
Adlai Nortye (ANL) Loss Narrows To US$18.3 Million Challenging Bearish Cash Burn Narrative - Sahm
FGI Industries, Nouveau Monde Graphite And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year? - qz.com
Adlai Nortye Reshapes Top Leadership as President Retires and R&D Chief Steps Up - The Globe and Mail
Is Adlai Nortye Ltd. sponsored ADR (ANL) outperforming other medical stocks this year? - MSN
Adlai Nortye Ltd. sponsored ADR (ANL) upgraded to buy: Here's why - MSN
Adlai Nortye Ltd. Sponsored ADR (ANL) Raised to Buy: The Reason Behind This Change - Bitget
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why - Yahoo Finance
ETFs Investing in Adlai Nortye Ltd. Sponsored ADR Stocks - TradingView
Analysts Offer Insights on Consumer Goods Companies: Clene (CLNN) and Ollie’s Bargain Outlet Holding (OLLI) - The Globe and Mail
Adlai Nortye (NASDAQ: ANL) files $600M shelf; 21.5M ADSs resale - Stock Titan
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Compass Therapeutics (CMPX) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Ionis Pharmaceuticals (IONS) and Axsome Therapeutics (AXSM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP) - The Globe and Mail
Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Adlai Nortye upgraded to Buy at H.C. Wainwright as AN9025 enters clinic - TipRanks
H.C. Wainwright upgrades Adlai Nortye stock rating to Buy with $16 target - Investing.com South Africa
Adlai Nortye Doses First Patient in Global Phase 1 Trial of Pan-RAS Inhibitor AN9025 - TipRanks
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - GlobeNewswire Inc.
Short Interest in Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Rises By 458.7% - MarketBeat
Adlai Nortye Secures $140 Million PIPE Financing to Support Oncology Pipeline - The Globe and Mail
Adlai Nortye raises $140 million in private placement By Investing.com - Investing.com South Africa
Adlai Nortye prices 64.6M shares at $2.17 in private placement - TipRanks
Adlai Nortye raises $140 million in private placement - Investing.com
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Large Decrease in Short Interest - Defense World
AIFU Inc. – Sponsored ADR (NASDAQ:AIFU) Short Interest Update - Defense World
Adlai Nortye Ltd Adr Stock (ANL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):